A growing trend of promoting blood-based Alzheimer’s disease tests on social media platforms like TikTok, Instagram, and Facebook is misleading healthy adults into misinterpreting ambiguous biomarkers as definite disease, according to a study published in the Journal of the American Geriatrics Society. Researchers warn that unverified online advertisements and commercial promotions for tests detecting abnormal proteins like p-tau217 can cause undue psychological stress, financial burdens, and missed opportunities to manage real, modifiable dementia risk factors.
Social Media Marketing of Alzheimer’s Biomarker Tests
The study examined 188 posts across major social networks that reached a collective audience of 114 million followers. Researchers found that approximately one-third of these posts actively promoted blood-based tests to asymptomatic individuals. Accounts with explicit financial interests were more than three times as likely to target healthy people with commercial testing pitches, according to the findings.
Dr. Jenna Smith of the University of Sydney’s School of Public Health, who co-authored the study, cautions that detecting elevated biomarker levels does not guarantee an individual will ever develop clinical dementia. Furthermore, commercial marketing often bypasses established clinical pathways, leaving patients without clear guidance on whether to enroll in preventive trials or alter medications.
Financial Costs and Clinical Realities
In Australia, commercial blood tests for Alzheimer’s can cost up to 400 Australian dollars and are not covered by Medicare.
Professor Susan Kurrle of the Australian and New Zealand Society for Geriatric Medicine emphasizes that these diagnostics should only be ordered when the pre-test probability of early Alzheimer’s is high. Qualified clinicians must conduct careful patient assessments rather than relying on direct-to-consumer digital channels.
Risks of False Positives and False Negatives
Misinterpreting blood tests creates two distinct clinical hazards for consumers:
- False Positives: Asymptomatic individuals who test positive may believe they face inevitable cognitive decline, exposing themselves to psychological distress, potential reputational risks, and unnecessary medical costs.
- False Negatives: A negative test result can breed false complacency, causing individuals to neglect proven lifestyle interventions that lower actual dementia risk, such as blood pressure control, regular exercise, and hearing care.
Public health authorities stress that blood-based biomarkers remain an adjunct to—rather than a substitute for—comprehensive clinical evaluations administered by licensed medical professionals.
Related reading